Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Instagram Outage Disrupts Thousands of U.S. Users 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
WASHINGTON, DC, Jan. 6, 2016 (GLOBE NEWSWIRE) -- The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected David Simmons, Chairman and CEO of PPD, as its 2016 Chairman, and John Hubbard, President and CEO of Bioclinica, as Vice Chairman.
"ACRO plays a vital role in promoting the interests of the CRO industry globally," said Simmons. "Not only does ACRO represent the industry on legislative and regulatory matters but, increasingly, the association helps build relationships with the sponsor, research site, investigator and patient communities. I look forward to leading the organization in 2016 as we pursue a focused and productive agenda."
|
|||||
Simmons added that, in addition to its legislative and regulatory priorities, ACRO is exploring further ways to benefit the industry in areas such as patient recruitment, workforce development and clinical trial efficiency.
"ACRO successfully advanced CRO industry interests in 2015 by influencing health and tax policy in the United States and navigating the implementation of the Clinical Trial Regulation in the European Union," said ACRO Executive Director Doug Peddicord, Ph.D. "We will build on our successes this year and continue to promote our industry through our robust communications and advocacy programs."
ACRO also elected as officers: Judd Hartman, General Counsel of PPD, as Treasurer; and Maria Kraus, Executive Vice President of Corporate Development and Strategy at Bioclinica, as Secretary.
About ACRO
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. The Association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 110,000 professionals worldwide and conduct research in 142 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook. RebelMouse.
A photo accompanying this release is available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=38345
CONTACT: John Lewis
[email protected]
202-464-9340
